Antineoplastics/radiotherapy
1
Reactions 556 - 24 Jun 1995 Antineoplastics/radiotherapy Carcinogenesis in patients with Hodgkin’s disease: incidence study The results of a case cohort study of 10 472 patients from the USA and Canada showed an increased risk of leukaemia and solid tumours in patients who received treatment with antineoplastics or radiotherapy for Hodgkin’s disease. 122 leukaemias and 438 solid tumours were observed amongst the group of patients. The median age at diagnosis of Hodgkin’s disease was 29 years and after excluding the first year after diagnosis, the average length of follow-up was 7.1 years per patient. Compared with controls, the overall relative risk of leukaemia and solid tumours following antineoplastic therapy was found to be 14 and 1.4, respectively, and the relative risk of leukaemia and solid tumours following radiotherapy was 1.2 and 0.9, respectively. Exposure to chlorambucil, procarbazine, vinblastine and a group of rarely used agents (including methotrexate, vindesine and etoposide) resulted in a statistically significant effect on leukaemia risk. Therapy with the combined regimen of mechlorethamine, vincristine, procarbazine and prednisone (MOPP) was associated with a relative risk of leukaemia of 5.9. For antineoplastic therapy the relative risk of cancers of the bones, joints, articular cartilage and soft tissues was 6 and the relative risk for cancers of the female genital system was 1.8. For those patients who were treated with radiotherapy and followed for over 10 years it was found that the relative risk of cancers of the respiratory system and intrathoracic organs was 2.7 and the relative risk for cancers of female genital system was 2.4. Author comment: ‘It is widely recognized that the benefits of treatment of Hodgkin’s disease, in terms of survival, outweigh the risk of a subsequent malignancy. The assessment of second cancer risk continues, however, to be essential in determining the balance of the risks and benefits of treatment.’ This study confirmed the well-known association between MOPP and leukaemia risk. Boivin J-F, et al. Incidence of second cancers in patients treated for Hodgkin’s disease. Journal of the National Cancer Institute 87: 732-741, 17 May 1995 - USA 800365235 1 Reactions 24 Jun 1995 No. 556 0114-9954/10/0556-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics/radiotherapy
Reactions 556 - 24 Jun 1995
Antineoplastics/radiotherapy
Carcinogenesis in patients with Hodgkin’s disease:incidence study
The results of a case cohort study of 10 472 patients fromthe USA and Canada showed an increased risk of leukaemiaand solid tumours in patients who received treatment withantineoplastics or radiotherapy for Hodgkin’s disease.
122 leukaemias and 438 solid tumours were observedamongst the group of patients. The median age at diagnosis ofHodgkin’s disease was 29 years and after excluding the firstyear after diagnosis, the average length of follow-up was 7.1years per patient.
Compared with controls, the overall relative risk ofleukaemia and solid tumours following antineoplastic therapywas found to be 14 and 1.4, respectively, and the relative riskof leukaemia and solid tumours following radiotherapy was1.2 and 0.9, respectively.
Exposure to chlorambucil, procarbazine, vinblastine and agroup of rarely used agents (including methotrexate, vindesineand etoposide) resulted in a statistically significant effect onleukaemia risk.
Therapy with the combined regimen of mechlorethamine,vincristine, procarbazine and prednisone (MOPP) wasassociated with a relative risk of leukaemia of 5.9.
For antineoplastic therapy the relative risk of cancers of thebones, joints, articular cartilage and soft tissues was 6 and therelative risk for cancers of the female genital system was 1.8.
For those patients who were treated with radiotherapy andfollowed for over 10 years it was found that the relative risk ofcancers of the respiratory system and intrathoracic organs was2.7 and the relative risk for cancers of female genital systemwas 2.4.
Author comment: ‘It is widely recognized that the benefitsof treatment of Hodgkin’s disease, in terms of survival,outweigh the risk of a subsequent malignancy. The assessmentof second cancer risk continues, however, to be essential indetermining the balance of the risks and benefits of treatment.’This study confirmed the well-known association betweenMOPP and leukaemia risk.Boivin J-F, et al. Incidence of second cancers in patients treated for Hodgkin’sdisease. Journal of the National Cancer Institute 87: 732-741, 17 May 1995 -USA 800365235
1
Reactions 24 Jun 1995 No. 5560114-9954/10/0556-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
